Eliem Therapeutics, Inc (ELYM) Financials

ELYM Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2023 112.7 million 3.0 million
June 30, 2023 116.3 million 3.8 million
March 31, 2023 122.1 million 5.2 million
Dec. 31, 2022 135.0 million 6.3 million

ELYM Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 3.5 million 656000
June 30, 2023 -8.0 million 777000
March 31, 2023 -15.2 million 10.2 million
Dec. 31, 2022 -8.4 million 1.9 million

ELYM Net Income

No data available :(

ELYM Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 107.4 million - 459000
June 30, 2023 102.6 million - 585000
March 31, 2023 109.4 million - 687000
Dec. 31, 2022 123.6 million - 480000

ELYM Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 27.1 million
June 30, 2023 26.8 million
March 31, 2023 26.5 million
Dec. 31, 2022 26.4 million

ELYM Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 - 2.9 million 2.1 million -
June 30, 2023 - 3.7 million 3.0 million -
March 31, 2023 - 5.7 million 17.7 million -
Dec. 31, 2022 - 4.9 million 4.6 million -

ELYM Cost of Revenue

No data available :(

ELYM

Price: $5.11

52 week price:
2.35
11.55

Earnings Per Share: -2.22 USD

P/E Ratio: -1.85

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 3200

Market Capitalization: 342.7 million

Links: